As per this report, the Market Data Forecast says, the Global NGS Market size is estimated to grow USD 3.63 billion by the end of 2020 and USD 8.54 billion by 2025, growing at a CAGR of 18.66% during the forecast period.
The next-generation sequencing (NGS) approach uses massively parallel processing in the formation of DNA sequencing. There are two methods in preparation of the templates, namely amplified template originated from single molecules and single DNA molecule templates. NGS plays a pivotal role in clinical practice by improving diagnosis procedures. This technique is mainly used in discovering disease-causing genes. It takes a single day to complete the entire human genome with this technique.
Increasing incidences of chronic diseases is undoubtedly a significant factor propelling the demand of the Global Next-Generation Sequencing Market. Growing investments in the research institutes in the biotechnology field are accelerating the growth of the market. The rise in need to improve diagnostic procedures and also to ensure quality treatment is propelling the development of this market.
Growing studies on genomes are likely to outshine the demand of the market. Increasing the geriatric population is also a common factor leveling up the growth rate of this next-generation sequencing market. Growth opportunities for the lie in the government's rising support in introducing reimbursement schemes in favor of the public.
Next-generation sequences will provide enormous cloud computing opportunities as potential data management services in the emerging markets offer numerous opportunities to the companies operating in this space. Opportunities will be delivered due to growth in the government initiatives for the genomics projects in large-scale industries like drug developments and research of the clinical diagnostics processes. Nowadays, the growing trend in medicine of personalized medical facilities in the next-generation sequencing market.
However, the cost of installation and maintenance of the equipment in laboratories is a bit expensive, which is slowly impeding the growth of the market. Lack of standardization is also an attribute limiting the demand of the NGS market.
The major challenge faced by the next-generation sequencing market is the interpretation of the data's DNA sequence, acceleration of the analysis of the data, shortage in the storage of the data generated in the bottleneck. There are serious issues like data originating from the diverse datasets usage, which needs to be addressed. Poor in records of the data sequences. Some DNA’s like short fragments should be analyzed and compared with the reference databases, which is against but efficient and fast. To face these many challenges, many solutions were proposed by the commercial software and industries, but still existing many hardships to handle.
Another significant challenge is updating the data to the central or disturbed data storage and analysis services by the clients' computers and the data parallelization using the grid or cloud solutions.
Next-generation sequences have a crucial and essential role in the clinical labs and research to fight against the SARScov-2, which results in the COVID-19. When the world is fighting against the dangerous disease that is COVD-19 pandemic, there is an evolution in the genome, giving vital insights on spreading the impact on the different people. To fight against the COVID-19, the researchers are, and scientists together found information by the next generation sequence. Flomics are the latest research findings active in monitoring and contributing to the specialty in the following generation sequencing field. It helps find the cruciality of the interaction between the viral and host genomes, which helps find the individuals levels of riskiness.
The next-generation sequence gives an idea with a deep understanding of the disease and the impact of the pandemic on humans' health. The biotech partners, which are national and international, made a joined force by the Flomics with the specialization of the NGS tests, which helps in the development of the solutions based on the cloud to detect the COVID-19. Transformation of the raw data into interpretable clinical information will help manage the pandemic without the bioinformatics expertise but within a few clicks from any place like a clinic, hospitals, and research laboratory.
Market Size Available
2019 to 2025
2020 to 2025
By Product, Technology, Application, and Region
Various Analyses Covered
Global, Regional & Country Level Analysis, Segment-Level Analysis, Drivers, Restraints, Opportunities, Challenges, PESTLE Analysis, Porter’s Five Forces Analysis, Competitive Landscape, Analyst Overview on Investment Opportunities
North America, Europe, Asia Pacific, Latin America, Middle East, and Africa
This research report on the global next-generation sequencing market has been segmented and sub-segmented based on the product, technology, application, and region.
Next-Generation Sequencing Market - By Product:
Based on the product, the services segment is leading with the highest shares of the market. The rise in the number of genetic disorders across the world is fuelling the demand for this segment. Additionally, the increase in the demand for the sequence-based products, the need for data management services on storing a large amount of data, adopting the genetic test within a short period, existing guidelines, and health reimbursement policies further help the segment to occupy the leading position.
Next-Generation Sequencing Market - By Technology:
Among the mentioned applications, the category of Targeted sequencing is expected to show the highest growth during the forecast period due to the growing capabilities for whole-genome sequencing. The whole Genome sequencing segment is projected to showcase a healthy growth rate over the forthcoming years.
Next-Generation Sequencing Market - By Application:
Based on the application, the diagnostics segment is accounted for the largest share in the NGS market in 2019 and estimated to happen the same throughout the forecast period. With a growing number of cancer cases worldwide, reimbursement policies from the government that are favorable towards NGS-based tests in the U.S. are majorly anticipating the growth of this segment.
Personalized medicine segment to have an attractive growth rate during the forecast period. Increasing awareness related to NGS, growing demand for independent drug treatment, and early detection or prevention of disorders are likely to enhance the segment growth during the analysis period.
Next-Generation Sequencing Market - By Region:
North America is poised to account for the prime market share in the global NGS market, followed by Europe. Due to increased technological innovations and growing investments in the field, North America is expected to register the highest CAGR and dominate the market during the forecast period. Market growth is driven by the advancement of NGS bioinformatics solutions and the presence of significant players in the region.
China is expected to grow at the highest CAGR showing with Y-O-Y Growth Rate between 20.3% to 30.6% range from 2019 to 2024. The presence of noteworthy developments in China and Japan to integrate new technologies and the development of healthcare, R&D, and clinical development frameworks of developing economies such as India and Australia have led the Asia Pacific market to witness rewarding growth throughout the forecast period.
KEY COMPANIES IN THE NGS MARKET
Noteworthy Companies leading the Global Next Generation Sequencing Market profiled in the report are Illumina, Thermo Fisher Scientific, Pacific Biosciences, Macrogen Inc., Partek Inc., Genomatix Software GmbH, Perkin Elmer inc., GATC Biotech Ag, Agilent Technologies Inc., Biomatters Ltd., BGI (Beijing Genomics Institute), Oxford Nanopore Technologies Ltd., DNASTAR Inc., Knome Inc., and Qiagen N.V.
KEY RECENT DEVELOPMENTS IN THE MARKET:
On July 08, 2020, Illumina has introduced software for whole-genome analysis to examine rare diseases. This software is helped in making it comfortable in identifying the genetic elements behind the rare diseases.
On July 16, 2019, DNASTAR launched Lasergene16, which involves a wide range of improvements for analyzing DNA or RNA and protein sequence data and advancements in analyzing protein structures.
On July 13, 2020, Thermo Fisher Scientific has made a strategic partnership with First Genetics JCS, concentrating on promoting NGS based diagnostics assays in Russia. This agreement allows the market for reproductive health testing and cancer diagnostics.
In April 2019, a set of guidelines was released by food and drug administration to design, develop, and validate the NGS tests. These guidelines help companies detect specific variants in a clinical setting with high accuracy and support innovative tools in the NGS-based tests.
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.2 Analysis Design
2.3 Research Phases
2.3.1 Secondary Research
2.3.2 Primary Research
2.3.3 Econometric Modelling
2.3.4 Expert Validation
2.4 Study Timeline
3.1 Executive Summary
3.2 Key Inferences
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 By Product
5.2 By Technology
5.2.1 Whole Targeted Re-Sequencing
5.2.2 Genome Sequencing
5.2.3 De Novo Sequencing
5.2.4 Exome Sequencing
5.3 By Application
5.3.2 Drug Discovery
5.3.3 Biomarker Discovery
5.3.4 Personalized Medicine
5.3.5 Agriculture and Animals Research
6. Geographical Analysis
6.1 North America
6.1.2 United States
6.3.5 South Korea
6.4 Latin America
6.4.5 Rest of Latin America
6.5 Middle East & Africa
6.5.2 Middle East
7.1 PESTLE analysis
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8.Market Leaders' Analysis
8.1 Illumina Inc.
8.1.2 Product Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.2 Thermo Fisher Scientific
8.3 Life Sciences (Roche)
8.4 Pacific Biosciences
8.5 Macrogen Inc.
8.6 Partek Inc.
8.7 Genomatix Software GmbH
8.8 Perkin Elmer inc.
8.9 GATC Biotech Ag
8.10 Agilent Technologies Inc.
8.11 Biomatters Ltd.
8.12 CLC Bio (Qiagen)
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10.1 Market Outlook
10.2 Investment Opportunities
a) List of Tables
b) List of Figures